Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure | Cardiovascular Diabetes
Study setting and patients In this double-blind, randomized trial, adult patients with type 2 diabetes received placebo or dapagliflozin 10 mg once daily for 12 months. The study began on…